--- title: "Savara Announces New Employment Inducement Grant | SVRA Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/289636055.md" description: "Savara Inc. (Nasdaq: SVRA) announced inducement equity awards for four new employees on June 11, 2026. The grants include options for 36,500 shares at $5.27 per share, RSUs for 42,500 shares vesting over two years, and PSUs for 8,000 shares tied to revenue targets. These awards were granted under the company's 2021 Inducement Equity Incentive Plan in compliance with NASDAQ Listing Rules." datetime: "2026-06-12T12:05:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289636055.md) - [en](https://longbridge.com/en/news/289636055.md) - [zh-HK](https://longbridge.com/zh-HK/news/289636055.md) generator: "portal-rs" --- # Savara Announces New Employment Inducement Grant | SVRA Stock News See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google Add on Google LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase 36,500 shares of the Company’s common stock, restricted stock units (RSUs) covering 42,500 shares of the Company’s common stock, and performance stock units (PSUs) covering 8,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company. The options have an exercise price of $5.27 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16th of the number of shares subject to the option on each quarterly anniversary of the employee’s first day of employment, subject to the employee’s continued employment on each such vesting date. The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, and PSUs vest in full upon the date the Company reports quarterly revenue above a specified target, in each case subject to the employee’s continued employment on such vesting date. **About Savara** Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI\*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, and LinkedIn. \*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20260612214793/en/ **Media and Investor Relations Contact** Savara Inc. Temre Johnson, Executive Director, Corporate Affairs ir@savarapharma.com Source: Savara Inc. ### Related Stocks - [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md) ## Related News & Research - [Savara grants new hires options for 74,500 shares at $5.37, RSUs for 64,500 shares](https://longbridge.com/en/news/296530754.md) - [SVRA: MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market](https://longbridge.com/en/news/295577539.md) - [Job-finding rates have fallen the most for America's most reliably-employed workers](https://longbridge.com/en/news/295947358.md) - [Glucotrack regains Nasdaq stockholders’ equity compliance, secures continued listing](https://longbridge.com/en/news/296101788.md) - [SpaceX Has Big Investors Like Nvidia, Google, and AMD. That Could Be Dangerous for You.](https://longbridge.com/en/news/296390988.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**